Summary of share price highs, lows and changes for Novo Nordisk
Historical stock prices
Current Share Price	DKK 51.58
52 Week High	DKK 64.16
52 Week Low	DKK 35.12
Beta	0.36
1 Month Change	6.70%
3 Month Change	22.17%
1 Year Change	3.10%
3 Year Change	-34.85%
5 Year Change	5.04%
Change since IPO	28,358.09%

Recent News & Updates

Seeking Alpha • Jul 26

Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That

Summary Novo Nordisk remains a ‘hold’ as persistent drug weakness offsets strong valuation and recent outperformance. NVO’s adjusted revenue declined 10.3% YoY, driven by Ozempic and Rybelsus weakness, despite profitability and cash flow improvements. Pipeline progress in obesity and diabetes, including CagriSema and Zenagamtide, offers potential but lacks near-term catalysts. Valuation appears cheap versus peers, but justified by market share loss and analyst expectations for further revenue and profit declines. Read the full article on Seeking Alpha

Analysis Article • Jun 19

Novo Nordisk (NVO) Stock Could Be 54.5% Undervalued After Its 90 Day Rebound

Novo Nordisk (NVO) continues to draw investor attention after recent share price moves, with the stock last closing at $43.19. The company’s performance metrics now invite closer scrutiny of its valuation and growth profile. See our latest analysis for Novo Nordisk. Recent trading has been slightly softer, with a 1-day share price return of 0.76% and a 7-day share price return of 1.75%. The 90-day share price return of 18.23% contrasts with a year to date share price decline of 17.56% and a...

Recent updates

Seeking Alpha • Jul 26

Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That

Analysis Article • Jun 19

Novo Nordisk (NVO) Stock Could Be 54.5% Undervalued After Its 90 Day Rebound

New Narrative • May 04

One of the two dominant players in a market projected to double, and possibly triple, over the next 5 to 8 years.

Catalysts Recent success in a phase IIIa trial showed once-daily doses of oral semaglutide demonstrated a statistically significant and superior reduction in HbA1c by 0.83% versus placebo at 26 weeks for adolescents with Type II diabetes. Based on the study data, NVO intends to seek regulatory approval for oral semaglutide in adolescents aged 10 to 17 with T2D for both Rybelsus and oral Ozempic in the U.S. and the EU in the second half of the year.

Narrative Update • Jan 06

Valuation reset, but the GLP-1 franchise (and optionality) remains intact

Novo Nordisk (NVO) has continued to face a tougher near-term backdrop, but the longer-term investment case remains intact. Management has narrowed 2025 guidance to 8–11% sales growth and 4–7% operating profit growth (constant exchange rates), explicitly citing intensifying competition and pricing pressure in both diabetes and obesity.

Analysis Article • Aug 05

Weekly Picks: ASML's Selloff Explained, WH's Global Expansion, and NVO's Market Mispricing

This week’s picks cover: Why now might be an opportune time to consider ASML, How Wyndham Hotels' loyalty revenue and global expansion are driving growth, and why Novo Nordisk's risk/reward case is better than it seems.

New Narrative • Aug 05

A Quality Compounder Marked Down on Overblown Fears

Policy pressure: US price cuts via the IRA and executive order

Seeking Alpha • Apr 26

Novo Nordisk: Examining Tariff And Pricing Risks

Summary Novo Nordisk has a strong balance sheet and high returns on equity, but faces challenges with its next-gen weight loss drug, CagriSema. Political risks, including potential US drug price normalization and tariffs, could impact Novo's profitability significantly. Despite competition, Novo's leadership in the weight loss drug market and growth potential make it a compelling buy at $50. With a 3.8% yield and solid EPS growth, Novo could offer attractive returns, assuming manageable political risks and continued market expansion. We consider the stock a hold at $62. Read the full article on Seeking Alpha

Seeking Alpha • Apr 18

Novo Nordisk: A Price Too Low To Ignore

Summary Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is disappointing results for its drug trials, though challenges like potential tariffs on Denmark, its home country, also play a part. Yet, the company's robust fundamentals, healthy outlook and attractive market multiples go in its favour, justifying a Buy rating. Read the full article on Seeking Alpha

Seeking Alpha • Mar 30

Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors

Summary Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of drugs and product candidates relative to the rival. Dear Seeking Alpha readers, you will discover whether Novo Nordisk or Eli Lilly is a more attractive stock in the long term. Read the full article on Seeking Alpha

Seeking Alpha • Mar 10

Novo Nordisk: CagriSema Disappoints Again

Summary Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy, with only 61.9% on the highest dose in the REDEFINE-2 trial. The efficacy data to date suggest CagriSema has similar efficacy to Eli Lilly's tirzepatide, and much better efficacy than semaglutide. Novo Nordisk plans to start the REDEFINE-11 trial to improve the efficacy of CagriSema, aiming for higher weight loss that could beat tirzepatide and potentially match Eli Lilly's retatrutide. Eli Lilly may have the upper hand in the obesity market, but I expect Novo Nordisk to remain a formidable competitor, with multiple other shots on goal in the clinic. Read the full article on Seeking Alpha

Seeking Alpha • Feb 20

Why Novo Nordisk Is A Strong Buy Despite Market Concerns

Summary Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly. So, sales of Ozempic and Wegovy amounted to DKK 53.7 billion in the fourth quarter of 2024, increasing by 35.4% year-on-year despite competition from Mounjaro. In addition, at the end of January 2025, Novo Nordisk published data from a phase 1b/2a clinical study with amycretin, which beat even my wildest expectations. In this article, you will learn why I believe Novo Nordisk is an attractive stock for long-term investors. Read the full article on Seeking Alpha

Shareholder Returns

	NVO	US Pharmaceuticals	US Market
7D	7.0%	3.4%	-2.6%
1Y	3.1%	50.5%	14.3%

Return vs Industry: NVO underperformed the US Pharmaceuticals industry which returned 50.5% over the past year.

Return vs Market: NVO underperformed the US Market which returned 14.3% over the past year.

Price Volatility

Is NVO's price volatile compared to industry and market?
NVO volatility
NVO Average Weekly Movement	4.7%
Pharmaceuticals Industry Average Movement	9.1%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stable Share Price: NVO has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: NVO's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1923	67,900	Maziar Doustdar	www.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NVO fundamental statistics
Market cap	US$227.67b
Earnings (TTM)	US$18.57b
Revenue (TTM)	US$49.92b

12.3x

P/E Ratio

4.6x

P/S Ratio

Is NVO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NVO income statement (TTM)
Revenue	DKK 327.80b
Cost of Revenue	DKK 55.09b
Gross Profit	DKK 272.72b
Other Expenses	DKK 150.76b
Earnings	DKK 121.96b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 05, 2026

Earnings per share (EPS)	27.57
Gross Margin	83.20%
Net Profit Margin	37.20%
Debt/Equity Ratio	67.7%

How did NVO perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

43%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/29 22:03
End of Day Share Price	2026/07/29 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 52 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	ABG Sundal Collier
Gerhard Schwarz	Baader Helvea Equity Research
José Romero Herrero	Banco Santander

Novo Nordisk (NVO) Stock Overview

Rewards

Risk Analysis

Top Community Narratives

One of the two dominant players in a market projected to double, and possibly triple, over the next 5 to 8 years.

Novo Nordisk will thrive with a 34.7751% profit margin boost

A Quality Compounder Marked Down on Overblown Fears

Top Community Narratives

One of the two dominant players in a market projected to double, and possibly triple, over the next 5 to 8 years.

Novo Nordisk will thrive with a 34.7751% profit margin boost

A Quality Compounder Marked Down on Overblown Fears

Novo Nordisk A/S Competitors

Merck

Bristol-Myers Squibb

Pfizer

Johnson & Johnson

Price History & Performance

Recent News & Updates

Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That

Novo Nordisk Receives European Commission Approval of Wegovy® Pill as First Oral Glp-1 for Weight Management in the Eu; Single, Ready-To-Use Pen for Higher Dose 7.2 Mg Also Approved

Novo Nordisk Presents Positive Long-Term Safety and Efficacy Results for Denecimig (Mim8) In Phase 3 Hemophilia a Frontier Extension Study

Novo Nordisk Announces Wegovy Now Accessible to Eligible Medicare Beneficiaries Living with Obesity Through Medicare GLP-1 Bridge

Novo Nordisk (NVO) Stock Could Be 54.5% Undervalued After Its 90 Day Rebound

Novo Nordisk Receives UK Approval For Wegovy Pill For Weight Management

Recent updates

Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That

Novo Nordisk Receives European Commission Approval of Wegovy® Pill as First Oral Glp-1 for Weight Management in the Eu; Single, Ready-To-Use Pen for Higher Dose 7.2 Mg Also Approved

Novo Nordisk Presents Positive Long-Term Safety and Efficacy Results for Denecimig (Mim8) In Phase 3 Hemophilia a Frontier Extension Study

Novo Nordisk Announces Wegovy Now Accessible to Eligible Medicare Beneficiaries Living with Obesity Through Medicare GLP-1 Bridge

Novo Nordisk (NVO) Stock Could Be 54.5% Undervalued After Its 90 Day Rebound

Novo Nordisk Receives UK Approval For Wegovy Pill For Weight Management

Novo Nordisk Launches Wegovy Pill in the United Arab Emirates

Novo Nordisk Presents Results from the POSEIDON Real-World Evidence Study on Cardiovascular Inflammation in People with Cardiovascular Disease

Novo Nordisk A/S Wegovy Pill Recommend by Chmp for Approval in Eu as First Oral Glp-1 for Obesity Treatment

Novo Nordisk to Unveil Data Showing Semaglutide Tackles the Liver Disease Crisis Affecting About 1 in 3 People Living with Overweight and Obesity Worldwide

Novo Nordisk Presents Wegovy Pill Clinical Trial Results and Product Updates

Novo Nordisk A/S Demonstrates Wegovy Delivers Substantial Weight Loss and Health Benefits for Women Across All Menopause Stages

Novo Nordisk A/S Demonstrates Higher Dose Wegovy Achieves Nearly 28% Weight Loss in Early Responders

One of the two dominant players in a market projected to double, and possibly triple, over the next 5 to 8 years.

Novo Nordisk Announces Positive Topline Results from Pioneer Teens Trial of Oral Semaglutide for Type 2 Diabetes in Children and Adolescents

Novo Nordisk Demonstrates Wegovy Pill At Obesity Medicine Association Conference

Novo Nordisk Announces Etavopivat Meets Co-Primary Endpoints in Phase 3 Hibiscus Trial for Sickle Cell Disease

Novo Nordisk A/S Receives Ema Approval for Controlled-Temperature Delivery of Wegovy Injection in Europe

Novo Nordisk A/S Announces Approval Of Awiqli Injection In The US

Novo Nordisk Announces FDA Approval of Awiqli Once-Weekly Basal Insulin for Adults with Type 2 Diabetes

Novo Nordisk A/S and The United Laboratories International Holdings Limited Announce Phase 2 Results For UBT251 In Chinese Patients With Type 2 Diabetes

Lexicon Pharmaceuticals And Novo Nordisk Initiate Phase 1 Study With Oral Obesity Drug Candidate LX9851

Novo Nordisk A/S Announces Wegovy Hd (Semaglutide 7.2 Mg) Approval in Us

Novo Nordisk A/S Announces Changes of Employee Representatives to the Board of Directors

The United Laboratories International Holdings Limited and Novo Nordisk A/S Announces Topline Results from A Chinese Phase 2 Trial of UBT251

Novo Nordisk's Wegovy Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral Glp-1S in Obesity

The European Commission Approves More Effective Dose of Injectable Wegovy® for Adults with Obesity; Clinical Study Showed People Lost About 21% of Their Body Weight on Average

Novo Nordisk A/S Proposes Final Dividend for Each Novo Nordisk A and B Share for the Year 2025

Novo Nordisk A/S Announces Headline Results from REIMAGINE 2

Novo Nordisk A/S Announces Change in Employee Representative on Board of Directors, Effective January 31, 2026

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

Valuation reset, but the GLP-1 franchise (and optionality) remains intact

LifeMD, Inc. Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy®? Pill

Novo Nordisk's Wegovy Pill, the First and Only Oral Glp-1 for Weight Loss in Adults, Now Broadly Available Across America

Novo Nordisk A/S Announces More Efficacious Dose of Wegovy®? Recommends by the European Medicines Agency

Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of Akero Therapeutics, Inc. (NasdaqGS:AKRO).

Novo Nordisk Presents New Topline Results from Their Evoke and Evoke+ Phase 3 Trials of Semaglutide

Novo Nordisk Phase 2 Trial with Amycretin Reports Significant Weight Loss and HbA1c Reduction in Type 2 Diabetes

Novo Nordisk Announces Top-Line Results from the 2-Year Primary Analysis of Evoke and Evoke+ Phase 3 Trials in Early-Stage symptomatic Alzheimer's Disease

Novo Nordisk A/S to Report Q1, 2026 Results on Mar 26, 2026

Novo Nordisk A/S, Annual General Meeting, Mar 26, 2026

Novo Nordisk A/S Approves Board Members

Novo Nordisk Presents New Findings from the Step Up Phase 3B Trial

Novo Nordisk A/S Revises Earnings Guidance for the Year 2025

Pfizer Inc. Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk A/S

Pfizer Inc. Files Lawsuit Against Metsera, Inc. and Novo Nordisk, S.A. for Breach of Merger Agreement

Novo Nordisk A/S (CPSE:NOVO B) submitted an unsolicited proposal to acquire Metsera, Inc. (NasdaqGS:MTSR) ) for approximately $6 billion.

Novo Nordisk A/S Announces Not to Stand Re-Election of Directors

Novo Nordisk A/S Receives Exclusive Global Rights to Develop and Commercialise Zaltenibart in All Indications

Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Akero Therapeutics, Inc. (NasdaqGS:AKRO) for approximately $4.4 billion.

Novo Nordisk Resubmits Awiqli®? to the FDA with Potential to Be the First Once-Weekly Insulin Icodec Treatment for Adults with Type 2 Diabetes

Novo Nordisk A/S Announces Results from the REACH Real-World Study

Novo Nordisk Presents Phase 3 Data for Next-Generation Amylin Amylin Cagrilintide, Leading to Advance into Dedicated Clinical Programme

Eu Approval Makes Novo Nordisk’S Oral Semaglutide the First and Only Oral Glp-1 Ra to Reduce Cardiovascular Death, Heart Attack and Stroke

Novo Nordisk Presents Data from the Steel Real-World Study of Evidence Grows from actual Patient Experiences at European Society of Cardiology Congress 2025